As of Feb 17
| -0.05 / -0.46%|
The 2 analysts offering 12-month price forecasts for Novelion Therapeutics Inc have a median target of 11.88, with a high estimate of 13.75 and a low estimate of 10.00. The median estimate represents a +10.16% increase from the last price of 10.78.
The current consensus among 3 polled investment analysts is to Hold stock in Novelion Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.